

CERTIFICATE OF ANALYSIS

* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

20210405MBHCFFHH (EXTRACT) // PRODUCED: APR 08, 2021

CLIENT: MERRY MEETING BAY HEMP COMPANY // BATCH: FAILED AS MAINE INDUSTRIAL HEMP



BATCH NO.: MYSTEXTRC
MATRIX: EXTRACT
SAMPLE ID: NAL-210405-015
COLLECTED ON: APR 05, 2021
RECEIVED ON: APR 05, 2021
SAMPLE SIZE: 6.18 GRAMS
RECEIVED BY: ANDREW PATTERSON

| CANNABINOID OVERVIEW | |
|----------------------------|-----------------|
| TOTAL THC: | 1.96 % |
| TOTAL CBD: | 81.6 % |
| TOTAL CANNABINOIDS: | 86.221 % |

CULTIVATOR INFO

CULTIVATOR
CHARLES F. GILL
P.O. BOX 36
BOWDOINHAM, MAINE 04008
(44.0091821, -69.8968927)

LICENSE
CGR28740
MEDICINAL - CAREGIVER

MANUFACTURER INFO

MANUFACTURER
CHARLES F. GILL
P.O. BOX 36
BOWDOINHAM, MAINE 04008

LICENSE
CGR28740
MEDICINAL - CAREGIVER

BATCH RESULT: FAILED AS MAINE INDUSTRIAL HEMP

| | |
|-------------------|--------|
| POTENCY | FAIL |
| METALS | TESTED |
| MYCOTOXINS | TESTED |
| PESTICIDES | TESTED |
| SOLVENTS | TESTED |
| TERPENES | TESTED |

DISTRIBUTOR INFO

DISTRIBUTOR: APR 07, 2021 // **ANALYSIS:** APR 08, 2021
CHARLES F. GILL

| ANALYTE | LIMIT | AMT | AMT | LOD/LOQ (%) | PASS/FAIL |
|----------------------|---------|-----------|-----|-------------|-----------|
| CBC | 1.73 % | 17.3 mg/g | | 0.182/0.909 | N/A |
| CBGA | ND | ND | | 0.182/0.909 | N/A |
| CBD | 81.6 % | 816 mg/g | | 0.182/0.909 | N/A |
| CBDA | ND | ND | | 0.182/0.909 | N/A |
| CBDV | ND | ND | | 0.182/0.909 | N/A |
| CBDVA | ND | ND | | 0.182/0.909 | N/A |
| CBG | 0.931 % | 9.31 mg/g | | 0.182/0.909 | N/A |
| CBGA | ND | ND | | 0.182/0.909 | N/A |
| CBL | ND | ND | | 0.182/0.909 | N/A |
| CBLA | ND | ND | | 0.182/0.909 | N/A |
| CBN | ND | ND | | 0.182/0.909 | N/A |
| CBNA | ND | ND | | 0.182/0.909 | N/A |
| Δ ⁸ -THC | ND | ND | | 0.182/0.909 | N/A |
| Δ ⁹ -THC | 1.96 % | 19.6 mg/g | | 0.182/0.909 | N/A |
| Δ ¹⁰ -THC | ND | ND | | 0.182/0.909 | N/A |

| ANALYTE | LIMIT | AMT | AMT | LOD/LOQ (%) | PASS/FAIL |
|-------------------------|-------|---------|-----------|-------------|-----------|
| EXO-THC | | ND | ND | 0.182/0.909 | N/A |
| THCA | | ND | ND | 0.182/0.909 | N/A |
| THCV | | ND | ND | 0.182/0.909 | N/A |
| THCVA | | ND | ND | 0.182/0.909 | N/A |
| TOTAL THC ** | | 1.96 % | 19.6 mg/g | | N/A |
| TOTAL CBD ** | | 81.6 % | 816 mg/g | | N/A |
| CBD/SRV | | 816 mg | | | N/A |
| Δ ⁹ -THC/SRV | | 19.6 mg | | | N/A |
| TOTAL CBD/SRV ** | | 816 mg | | | N/A |
| TOTAL THC/SRV ** | | 19.6 mg | | | N/A |
| CBD/PKG | | 816 mg | | | N/A |
| Δ ⁹ -THC/PKG | | 19.6 mg | | | N/A |
| TOTAL CBD/PKG ** | | 816 mg | | | N/A |
| TOTAL THC/PKG ** | | 19.6 mg | | | N/A |

** TOTAL THC = (THCA X 0.877) + THC
** TOTAL CBD = (CBDA X 0.877) + CBD
Reported on an as received basis
1000 µg/g = 1 mg/g



RESULTS CERTIFIED BY:
BARRY CHAFFIN
COO, NOVA ANALYTIC LABS
APR 08, 2021

RESULTS CERTIFIED BY:
GREG NEWLAND
CSO, NOVA ANALYTIC LABS
APR 08, 2021

RESULTS CERTIFIED BY:
CHRIS ALTOMARE
CEO, NOVA ANALYTIC LABS
APR 08, 2021

**TERPENES BY HEADSPACE GC-MS
PREPARATION: APR 06, 2021 // ANALYSIS: APR 07, 2021**

| ANALYTE | AMT | AMT | LOD/LOQ | PASS/FAIL |
|----------------|-----------|-------------|---------|-----------|
| TOTAL TERPENES | 7.76 % | 77.6 mg/g | | N/A |
| CAMPHENE | 0.0105 % | 0.105 mg/g | | N/A |
| GERANIOL | ND | ND | | N/A |
| LINALOOL | 0.225 % | 2.25 mg/g | | N/A |
| P-CYMENE | 0.00426 % | 0.0426 mg/g | | N/A |
| EUCALYPTOL | 0.00356 % | 0.0356 mg/g | | N/A |
| ISOPULEGOL | 0.0175 % | 0.175 mg/g | | N/A |
| D-LIMONENE | 0.461 % | 4.61 mg/g | | N/A |
| TERPINOLENE | 0.0444 % | 0.444 mg/g | | N/A |
| β-PINENE | 0.120 % | 1.20 mg/g | | N/A |
| α-PINENE | 0.404 % | 4.04 mg/g | | N/A |
| β-MYRCENE | 4.26 % | 42.6 mg/g | | N/A |

| ANALYTE | AMT | AMT | LOD/LOQ | PASS/FAIL |
|------------------------|-----------|-------------|---------|-----------|
| β-OCIMENE | 0.0297 % | 0.297 mg/g | | N/A |
| α-OCIMENE | 0.414 % | 4.14 mg/g | | N/A |
| CIS-NEROLIDOL | 0.0390 % | 0.390 mg/g | | N/A |
| Δ ³ -CARENE | 0.00810 % | 0.0810 mg/g | | N/A |
| α-HUMULENE | 0.330 % | 3.30 mg/g | | N/A |
| α-BISABOLOL | 0.116 % | 1.16 mg/g | | N/A |
| α-TERPINENE | 0.0123 % | 0.123 mg/g | | N/A |
| B-CARYOPHYLLENE | 1.08 % | 10.8 mg/g | | N/A |
| γ-TERPINENE | 0.00565 % | 0.0565 mg/g | | N/A |
| TRANS-NEROLIDOL | 0.104 % | 1.04 mg/g | | N/A |
| CARYOPHYLLENE OXIDE | 0.0750 % | 0.750 mg/g | | N/A |

**RSOL.1: RESIDUAL SOLVENTS, POISONS AND TOXINS BY HEADSPACE GC-MS
PREPARATION: APR 06, 2021 // ANALYSIS: APR 07, 2021**

| ANALYTE | LIMIT | AMT (µg/g) | LOD/LOQ (µg/g) | PASS/FAIL |
|----------|-----------|------------|----------------|-----------|
| BUTANE | 5000 µg/g | 561 | 12.1/24.2 | N/A |
| HEXANE | 290 µg/g | ND | 12.1/24.2 | N/A |
| ACETONE | 5000 µg/g | 15.8 | 6.06/12.1 | N/A |
| BENZENE | 1 µg/g | ND | 0.606/1.21 | N/A |
| ETHANOL | 5000 µg/g | 142 | 12.1/24.2 | N/A |
| HEPTANE | 5000 µg/g | ND | 12.1/24.2 | N/A |
| PENTANE | 5000 µg/g | ND | 12.1/24.2 | N/A |
| PROPANE | 5000 µg/g | ND | 12.1/24.2 | N/A |
| TOLUENE | 890 µg/g | ND | 12.1/24.2 | N/A |
| METHANOL | 3000 µg/g | ND | 12.1/24.2 | N/A |
| O-XYLENE | 2170 µg/g | ND | 3.03/6.06 | N/A |

| ANALYTE | LIMIT | AMT (µg/g) | LOD/LOQ (µg/g) | PASS/FAIL |
|------------------------|-----------|------------|----------------|-----------|
| CHLOROFORM | 1 µg/g | ND | 0.606/1.21 | N/A |
| ETHYL ETHER | 5000 µg/g | ND | 12.1/24.2 | N/A |
| ACETONITRILE | 410 µg/g | ND | 6.06/12.1 | N/A |
| ETHYL ACETATE | 5000 µg/g | ND | 12.1/24.2 | N/A |
| ETHYLENE OXIDE | 1 µg/g | ND | 0.606/1.21 | N/A |
| P- AND M-XYLENE | 2170 µg/g | ND | 1.21/2.42 | N/A |
| ISOPROPYL ALCOHOL | 5000 µg/g | ND | 12.1/24.2 | N/A |
| TRICHLOROETHY- LENE | 1 µg/g | ND | 0.606/1.21 | N/A |
| 1,2- DICHLOROETHANE | 1 µg/g | ND | 0.606/1.21 | N/A |
| METHYLENE CHLORIDE | 1 µg/g | ND | 0.606/1.21 | N/A |

**PES.1: PESTICIDES, INSECTICIDES, FUNGICIDES AND GROWTH REGULATORS BY LC-MS/MS
PREPARATION: APR 06, 2021 // ANALYSIS: APR 06, 2021**

| ANALYTE | LIMIT | AMT (µg/kg) | LOD/LOQ (µg/kg) | PASS/FAIL |
|------------|-------|-------------|-----------------|-----------|
| IMAZALIL | | ND | 0.815/3.26 | N/A |
| ETOXAZOLE | | ND | 0.815/3.26 | N/A |
| BIFENTHRIN | | ND | 0.815/4.34 | N/A |
| CYFLUTHRIN | | ND | 0.815/4.34 | N/A |

| ANALYTE | LIMIT | AMT (µg/kg) | LOD/LOQ (µg/kg) | PASS/FAIL |
|----------------------|-------|-------------|-----------------|-----------|
| DAMINOZIDE | | ND | 0.815/3.26 | N/A |
| MYCLOBUTANIL | | ND | 0.815/3.26 | N/A |
| SPIROMESIFEN | | ND | 0.815/3.26 | N/A |
| TRIFLOXYSTROB- IN | | ND | 0.815/3.26 | N/A |

**MYC.1: MYCOTOXINS BY LC-HRMS
PREPARATION: APR 07, 2021 // ANALYSIS: APR 08, 2021**

| ANALYTE | LIMIT | AMT (µg/kg) | LOD/LOQ (µg/kg) | PASS/FAIL |
|--------------|-------|-------------|-----------------|-----------|
| AFLATOXIN B1 | | ND | 0.300/0.900 | N/A |
| AFLATOXIN B2 | | ND | 0.900/1.50 | N/A |
| AFLATOXIN G1 | | ND | 0.300/0.900 | N/A |

| ANALYTE | LIMIT | AMT (µg/kg) | LOD/LOQ (µg/kg) | PASS/FAIL |
|--------------|-------|-------------|-----------------|-----------|
| AFLATOXIN G2 | | ND | 0.300/1.50 | N/A |
| OCHRATOXIN A | | ND | 0.600/1.80 | N/A |

**HME.1: HEAVY METALS BY ICP-MS
PREPARATION: APR 06, 2021 // ANALYSIS: APR 07, 2021**

| ANALYTE | LIMIT | AMT (µg/kg) | LOD/LOQ (µg/kg) | PASS/FAIL |
|---------|-----------|-------------|-----------------|-----------|
| LEAD | 500 µg/kg | < LOQ | 42.9/129 | N/A |
| ARSENIC | 200 µg/kg | ND | 42.9/107 | N/A |

| ANALYTE | LIMIT | AMT (µg/kg) | LOD/LOQ (µg/kg) | PASS/FAIL |
|---------|-----------|-------------|-----------------|-----------|
| CADMIUM | 200 µg/kg | ND | 42.9/107 | N/A |
| MERCURY | 100 µg/kg | ND | 42.9/85.7 | N/A |

* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

ALL TESTS WERE PERFORMED IN ACCORDANCE WITH THE RULES AND REGULATIONS SET FORTH IN THE MAINE ADULT USE PROGRAM. LABORATORY SAMPLING PROTOCOLS ARE GOVERNED BY THE OMP'S SAMPLING GUIDANCE DOCUMENTS. ALL INFORMATION PROVIDED BY THE CLIENT, INCLUDING SELF SAMPLING, MUST BE ACCURATE AND ADHERE TO THE SAME RULES AND REGULATIONS. HOWEVER, CLIENT PROVIDED INFORMATION, INCLUDING SAMPLING, IS ULTIMATELY THE RESPONSIBILITY OF THE PROVIDING LICENSEE, REGISTERED CAREGIVER, PATIENT OR THE LIKE AND FAILURE TO FOLLOW SAID PROTOCOLS COULD LEAD TO ERRONEOUS TEST RESULTS. NOTE: NOT ALL POTENTIAL AND/OR EXISTING HAZARDS WERE ANALYZED.

END OF REPORT

